Alex Schepart

A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma

Isha Mol, Yannan Hu, Thomas W. LeBlanc et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2024 · 16 citations · Full text

Medicine, Oncology, Pharmacology +15

Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma

Luciano J. Costa, Thomas W. LeBlanc, Hans Tesch et al. · Future Oncology · 2024 · 14 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma

Isha Mol, Yannan Hu, Thomas W. LeBlanc et al. · Current Medical Research and Opinion · 2023 · 12 citations

Medicine, Pharmacology, Pharmacotherapy +17

Medicare characteristics, treatment, cost and survival in triple class exposed relapsed or refractory multiple myeloma

Patrick Hlavacek, Alex Schepart, Alison R. Silverstein et al. · Future Oncology · 2023 · 10 citations · Full text

Medicine, Oncology, Pharmacoeconomics +13